Regeneron Pharmaceuticals and Sanofi are collaborating on a Phase 4 clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway ...

Patients with chronic rhinosinusitis with nasal polyps show high treatment persistence with dupilumab, with a substantial proportion restarting therapy after discontinuation.

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

The broader Sanofi and Regeneron COPD clinical research program includes Phase 3 trials with itepekimab, a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL-33).

Sanofi (SNY) and Regeneron's Dupixent (dupilumab) won approval for the additional indication of COPD in September 2024, making it the only biologic currently approved in the U.S. for the condition.

News provided by Regeneron Pharmaceuticals, Inc. Feb 16, 2024, 12:59 AM ET Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the ...